churc1 Antibody

What is CHURC1 and what is its functional significance in cellular processes?

CHURC1 (churchill domain containing 1), also known as C14orf52 or chch, is a protein that has not been extensively characterized but appears to play significant roles in developmental processes. It functions as a potential transcriptional activator that mediates fibroblast growth factor (FGF) signaling during neural development . According to zebrafish model studies, CHURC1 is predicted to enable zinc ion binding activity and participates in several critical processes including cell migration during gastrulation, FGF receptor signaling involved in somitogenesis, and negative regulation of FGF receptor signaling pathways . The protein is expressed in multiple structures including the digestive system, ethmoid cartilage, forerunner cell group, keratinocytes, and mucus-secreting cells . Its molecular weight is consistently observed at approximately 13 kDa across different detection methods and species .

In what experimental applications are CHURC1 antibodies commonly utilized?

CHURC1 antibodies have been validated for several common laboratory techniques in protein detection and localization studies. The primary applications include:

Researchers should note that each specific antibody may perform differently across these applications, making validation in your specific experimental system critical to success .

What species reactivity can be expected from commercially available CHURC1 antibodies?

Most commercially available CHURC1 antibodies demonstrate consistent cross-reactivity across human, mouse, and rat samples . This multi-species reactivity makes these antibodies versatile tools for comparative studies between model organisms and human samples. According to validation data, positive Western blot detection has been confirmed in mouse skin tissue, mouse liver tissue, and human cell lines such as HeLa . For immunohistochemistry applications, positive detection has been validated in human brain tissue, human gliomas tissue, and human kidney tissue . When planning experiments with other species, it is advisable to check sequence homology or conduct preliminary validation tests to confirm reactivity before proceeding with full-scale experiments.

How should I optimize CHURC1 antibody dilutions for different experimental applications?

Optimizing antibody dilutions is critical for achieving the best signal-to-noise ratio in your experiments. For CHURC1 antibodies, the recommended starting dilutions vary by application:

For optimal results, it is strongly recommended to perform a dilution series for each new lot of antibody and each experimental system. Factors that may influence optimal dilution include the abundance of CHURC1 in your specific samples, fixation methods, tissue type, and detection system used . As noted in technical specifications, "It is recommended that this reagent should be titrated in each testing system to obtain optimal results" . Document all optimization steps methodically for reproducibility in future experiments.

What antigen retrieval methods are recommended for CHURC1 immunohistochemistry?

Effective antigen retrieval is crucial for successful CHURC1 immunohistochemistry, particularly in formalin-fixed, paraffin-embedded tissues where epitope masking can occur. Based on technical documentation:

• The primary recommended method utilizes TE buffer at pH 9.0 .

• Alternatively, citrate buffer at pH 6.0 can be used if the primary method yields suboptimal results .

When implementing these methods, consider these procedural details:

• Heat-induced epitope retrieval (HIER) is typically more effective than enzymatic methods for nuclear proteins like CHURC1

• Optimize both the buffer composition and the heating parameters (time and temperature)

• Include both positive and negative controls to validate your retrieval protocol

• Document the exact protocol used for future reproducibility

Remember that over-retrieval can lead to non-specific staining while under-retrieval may result in false negatives, making careful optimization essential for reliable results.

How can I validate the specificity of a CHURC1 antibody in my experimental system?

Validating antibody specificity is a critical step before conducting extensive experiments. For CHURC1 antibody validation, implement the following comprehensive approach:

• Positive control tissues/cells: Include known CHURC1-expressing samples such as mouse skin tissue, mouse liver tissue, or HeLa cells for Western blot applications, and human brain tissue, human gliomas tissue, or human kidney tissue for IHC applications .

• Molecular weight verification: Confirm that the detected band appears at the expected molecular weight of 13 kDa in Western blot applications .

• Knockout/knockdown validation: When possible, include CHURC1 knockout or knockdown samples as negative controls to confirm antibody specificity.

• Peptide competition assay: Pre-incubate the antibody with its immunizing peptide before application to demonstrate specific binding.

• Multiple antibody validation: When critical findings depend on CHURC1 detection, consider validating with a second antibody raised against a different epitope of the same protein.

What considerations are important when using CHURC1 antibodies in multiplex immunostaining?

Multiplex immunostaining with CHURC1 antibodies requires careful planning to avoid cross-reactivity and signal interference. Consider these methodological approaches:

• Antibody selection: Choose CHURC1 antibodies from different host species than other target antibodies in your multiplex panel to avoid secondary antibody cross-reactivity .

• Sequential detection: For particularly challenging multiplex panels, consider sequential rather than simultaneous detection, with complete blocking or stripping between rounds.

• Spectral separation: When using fluorescent detection, ensure adequate spectral separation between fluorophores to prevent bleed-through:

  • For CHURC1 (13 kDa) and other small proteins, choose fluorophores that maximize signal-to-noise ratio

  • Consider brightness hierarchy based on expected abundance of targets

• Validation controls: Include single-stain controls alongside multiplex samples to verify staining patterns and intensity.

• Signal amplification considerations: If using tyramide signal amplification or other amplification methods, be aware that the order of detection can impact results, and optimization of the sequence may be necessary.

The rabbit polyclonal nature of most commercial CHURC1 antibodies should be considered when planning multiplex panels, as this may limit combinations with other rabbit-derived antibodies unless specialized detection systems are employed.

How can computational approaches improve CHURC1 antibody specificity for research applications?

Recent advances in computational antibody engineering offer promising approaches to enhance CHURC1 antibody specificity. These methods are particularly valuable when discriminating between closely related epitopes:

• Model-guided epitope selection: Biophysics-informed modeling can identify unique regions of CHURC1 that maximize specificity while maintaining binding affinity .

• High-throughput sequencing analysis: Deep sequencing of phage display experiments can identify specific binding modes associated with particular ligands, allowing for the computational design of antibodies with customized specificity profiles .

• Binding mode identification: As described in recent research, "The identification of different binding modes, each associated with a particular ligand against which the antibodies are either selected or not" can help disentangle complex binding interactions, even for chemically similar ligands .

• Optimization algorithms: Computational methods can be employed to "jointly minimize the functions associated with the desired ligand" for cross-specific sequences or "minimize associated with the desired ligand and maximize the ones associated with undesired ligands" for highly specific sequences .

These computational approaches complement traditional experimental methods and can significantly reduce the time and resources required to develop highly specific antibodies for challenging targets like CHURC1. While these techniques require specialized expertise, they represent the frontier of antibody engineering for research applications.

What factors might contribute to discrepancies in CHURC1 detection between different experimental techniques?

When investigating CHURC1, researchers sometimes encounter discrepancies between detection methods. Understanding the potential sources of these variations is crucial for accurate data interpretation:

• Epitope accessibility differences:

  • In Western blot, denaturation exposes all linear epitopes, while in IHC/ICC, only accessible epitopes in the fixed conformation are detected

  • The zinc-binding domain of CHURC1 may adopt different conformations depending on experimental conditions

• Post-translational modifications:

  • Different techniques may vary in their ability to detect modified forms of CHURC1

  • Consider that CHURC1's role in signaling pathways suggests potential regulatory modifications

• Expression level thresholds:

  • Western blot may detect accumulated protein below the visualization threshold of IHC

  • Differences in detection sensitivity between applications (WB: 1:200-1:1000 vs. IHC: 1:20-1:200) reflect this variation

• Cross-reactivity profiles:

  • Different techniques may reveal different cross-reactivity patterns

  • When discrepancies occur, orthogonal validation becomes essential

• Sample preparation effects:

  • Fixation can mask epitopes differently than extraction buffers used for Western blot

  • The small size of CHURC1 (13 kDa) makes it particularly susceptible to extraction and fixation artifacts